Roth Capital Downgrades Inovio Pharmaceuticals (INO) to Sell
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.12 +2.75%
Rating Summary:
11 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Rating Summary:
11 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Join SI Premium – FREE
Roth Capital analyst Jonathan Aschoff downgraded Inovio Pharmaceuticals (NASDAQ: INO) from Neutral to Sell with a price target of $11.00.
For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.
Shares of Inovio Pharmaceuticals closed at $25.00 yesterday.
You May Also Be Interested In
- Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
- B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral
- JPMorgan Downgrades EyePoint Inc. (EYPT) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
